Talon Resources Targets Ontario Gold Growth After AIM Move and Eagle Lake Acquisition, CEO Says.Watch here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksInspiration Hlt Regulatory News (IHC)

Share Price Information for Inspiration Hlt (IHC)

Share Price is delayed by 15 minutes
Get Live Data
22.00    0.00 (0.00%)
Bid:
21.00
Ask:
23.00
Spread: 2.00 (9.524%)
Market Cap: £20.17m
IHC Live PriceLast checked at - London Stock Exchange

Intraday Inspiration Hlt Share Chart

Interim Results

27 Sep 2012 07:00

RNS Number : 2554N
Inditherm PLC
27 September 2012
Β 

ο»Ώ

Β 

Press release

27 September 2012

Β 

Inditherm plc

("Inditherm" or "the Company")

Β 

Interim Results

Β 

Inditherm plc, the provider of innovative heating solutions, is pleased to announce its Interim Results for the six months ended 30 June 2012.

Β 

Highlights

Β·;

Revenue of Β£812k (2011: Β£817k)

Β·;

Loss on ordinary activities before taxation held at Β£73k (2011: Β£74k)

Β·;

Encouraging first quarter but second quarter reflected the difficult economic conditions in many markets, which were compounded by issues in the NHS

Β·;

Cash consumption from operating and investing activities for the 6 months was Β£97k (2011: Β£183k)

Β·;

Cash and cash equivalents at 30 June 2012 of Β£1.5m

Β 

Commenting on the outlook, Mark Abrahams, Chairman of Inditherm, said:

Β "We expect to show reasonable growth in the UK market this year following the stimulation provided by the NICE guidance, however we are less confident of growth in the export sector.

Β 

"Overall, we continue to believe in the growth potential in this business, albeit we recognise that there will be a slowdown of growth this year."

Β 

- Ends -

Β 

Β 

Β 

For further information:

Β 

Inditherm plc

Nick Bettles, Chief Executive

nbettles@indithermplc.com

Tel: +44 (0) 1709 761000

Ian Smith, Finance Director

ismith@indithermplc.com

www.inditherm.com

Β 

Media enquiries:

Abchurch

Sarah Hollins / Simone Elviss

simone.elviss@abchurch-group.com

Tel: +44 (0) 20 7398 7714

Β 

Β 

Canaccord Genuity Limited (Nomad)

Henry Fitzgerald-O'Connor

Tel: +44 (0) 20 7523 8350

Β 

Chairman's Statement

Β 

Introduction

The results for the first half of 2012 are almost a mirror image of the prior year performance. After an encouraging first quarter, the second quarter reflected the difficult economic conditions in many markets, compounded by issues in the NHS. This is somewhat of a disappointment following our efforts to reap the rewards from the recent support from the National Institute for Health and Clinical Excellence (NICE) recommendation issued in August 2011.

Β 

Trading in general has been more difficult with the economic pressure reflecting in slow conversion and smaller average order values. Nevertheless significant activity by our sales team has led to a healthy level of enquiries which we believe will realistically produce growth despite slow actual orders in the second quarter.

Β 

Financial Review

Revenue was flat at Β£812k (2011: Β£817k). Administrative expenses were reduced to Β£549k (2011: Β£593k). This held the loss on ordinary activities before taxation at Β£73k (2011: Β£74k), resulting in a loss per share of 0.1p (2011: 0.1p).

Β 

The cash consumption from operating and investing activities for the 6 months was Β£97k (2011: Β£183k), giving a balance of cash and cash equivalents of Β£1,531k in hand at the half year (31 December 2011: Β£1,628k).

Β 

Operational Review

Trading levels in the Medical business in the first quarter of 2012 continued the positive trend established in the last four months of 2011, with modest profit generated. However protracted decision making and uncertainty in the NHS, combined with a slow start to the year in many of our export markets, led to a fall in Medical turnover in the second quarter.

Β 

We have seen a pick up in orders from the NHS more recently which brings the UK back into growth once more. However, the underlying inertia in the NHS often delays recognition of our strong value proposition.

Β 

Β 

Β 

Following the NICE recommendations we have seen significant interest being shown by NHS hospitals although the bulk of this is yet to translate into orders, with only a few prospects already converted. The level of uncertainty gives cause for us to exercise caution in our forecasting.

Β 

Orders from overseas distributors (excluding the USA) were down by 5% at the end of June compared to the same period in 2011. Conversion rates are slower than would be expected and export markets appear to be suffering from macro-economic factors; however many of our distributors continue to give a positive outlook. A distributor conference was held in September and we anticipate this will stimulate activity levels. We continue to expand our distribution coverage and believe that a return to growth can be achieved.

Β 

The US Medical sector has remained slow but we believe that good prospects exist and, though we are limited in the resources that we can afford to dedicate to this region. We endeavour to support our distribution network to achieve its potential.

Β 

We continue to expand our product range, giving opportunities for additional future growth. A number of the OEM opportunities we are pursuing are progressing and, whilst there is no guarantee of success, these hold out the possibility of a step increase in sales in the future.

Β 

The level of Industrial orders from the retained standard product activities continues to make a positive contribution. We have seen a steady and encouraging level of orders this year for process applications, from our Industrial partner. Overall the Industrial business has held steady with order levels to the end of August comparable to the same period last year.

Β 

Outlook

The continuing economic difficulties in many of our export markets are to some extent being offset by wider recognition of our offering. Nevertheless we cannot be confident that we can deliver growth in exports this year, due to the lower average order sizes which we have been experiencing.

Β 

Β 

Β 

Β 

Our prospects for the UK have shown a progressive rise over the last twelve months, stimulated by the guidance for our technology from NICE, and leave us with a strong belief that we can show reasonable growth in our home market in 2012 compared to last year.

Β 

Overall, we continue to believe in the growth potential in this business, albeit we recognise that there will be a slowdown of growth this year.

Β 

Β 

Mark Abrahams, Chairman

27 September 2012

Β 

Β 

Β 

Β 

Β 

Unaudited consolidated statement of comprehensive income

For the six months ended 30 June 2012

Β 

Audited

Β 6 months

Β 6 months

Year

ended

ended

ended

30-Jun

30-Jun

31-Dec

2012

2011

2011

Notes

Β£'000

Β£'000

Β Β£'000

Turnover

812

817

1,659

Cost of sales

(342)

(303)

(659)

Gross profit

470

514

1,000

Administrative expenses

(549)

(593)

(1,131)

Operating loss

(79)

(79)

(131)

Finance income

6

5

10

Loss on ordinary activities before taxation

(73)

(74)

(121)

Taxation credit from loss on ordinary activities

1

-

-

13

Loss for the period attributable to equity shareholders

(73)

(74)

(108)

Loss per share from total Inditherm Group attributable to equity holders of the Company during the period - basic and diluted

2

(0.1p)

(0.1p)

(0.2p)

Β 

Β 

Β 

Β 

AllΒ recognisedΒ gainsΒ andΒ lossesΒ areΒ includedΒ inΒ theΒ income statement as such there is no other comprehensive income.

Β 

There is no difference between the results stated above and those prepared on the basis of historic cost equivalents.Unaudited consolidated balance sheet

As at 30 June 2012

Β 

Β 

Audited

6 months

6 months

Year

ended

ended

ended

30 June

30 June

31 December

2012

2011

2011

Β£'000

Β£'000

Β Β£'000

Assets

Non-current assets

Property, plant and equipment

24

35

26

Intangible assets

37

67

50

61

102

76

Current assets

Inventories

173

183

165

Trade and other receivables

257

359

233

Tax receivable

13

25

13

Cash and cash equivalents

1,531

1,518

1,628

1,974

2,085

2,039

Liabilities

Current liabilities

Trade and other payables

(227)

(276)

(238)

Net current assets

1,747

1,809

1,801

Net assets

1,808

1,911

1,877

Shareholders' equity

Called up share capital

511

511

511

Share premium account

9,929

9,929

9,929

Share based payment reserve

138

134

134

Retained earnings

(8,770)

(8,663)

(8,697)

Total equity

1,808

1,911

1,877

Β 

Β 

Β 

Β 

Β 

Β 

Β 

Β 

Β 

Β 

Β 

Unaudited consolidated cash flow statement

For the six months ended 30 June 2012

Β 

Audited

6 months

6 months

Year

ended

ended

ended

30 June

30 June

31 December

2012

2011

2011

Group and Company

Β£'000

Β£'000

Β Β£'000

Operating loss for the period

(79)

(79)

(131)

Profit on disposal of property, plant and equipment

-

-

(4)

Depreciation and amortisation

25

32

64

Share based payments

4

-

-

Increase in inventories

(8)

(51)

(33)

(Increase)/decrease in trade and other receivables

(24)

(121)

5

(Decrease)/increase in trade and other payables

(11)

38

-

Interest received

6

5

10

Taxation received

-

7

32

Net cash outflow from operating activities

(87)

(169)

(57)

Cash flow from Investing activities

Purchase of property, plant and equipment

(8)

(5)

(7)

Capitalised development costs

(2)

(9)

(13)

Proceeds from sale of property, plant and equipment

-

-

4

Net cash used in investing activities

(10)

(14)

(16)

Net decrease in cash and cash equivalents

(97)

(183)

(73)

Cash and cash equivalents at the beginning of the period

1,628

1,701

1,701

Cash and cash equivalents at the end of the period

1,531

1,518

1,628

Β 

Β 

Unaudited consolidated statement of changes in shareholder equity

For the six months ended 30 June 2012

Β 

Β 

Audited

6 months

6 months

Year

ended

ended

ended

30 June

30 June

31 December

2012

2011

2011

Β£'000

Β£'000

Β£'000

Opening shareholders' equity

1,877

1,985

1,985

Loss for the period

(73)

(74)

(108)

Share based payments

4

-

-

Closing shareholders' equity

1,808

1,911

1,877

Β 

Β 

Β 

NotesΒ toΒ theΒ interimΒ report

Β 

1. Basis of Preparation

Β 

This condensed consolidated interim financial information for the six months ended 30 June 2012 has been prepared in accordance with AIM rule 18 in relation to half year reports. This information should be read in conjunction with the annual financial statements for the year ended 31 December 2011, which have been prepared in accordance with International Financial Reporting Standards (IFRS) as adopted by the European Union.

Β 

2. Going-concern basis

Β 

The group meets its day-to-day working capital requirements through its cash resources. The current economic conditions continue to create uncertainty particularly over the level of demand for the group's products. The group's forecasts and projections, taking account of reasonably possible changes in trading performance, show that the group should be able to operate within the level of its current resources. After making enquiries, the directors have a reasonable expectation that the group has adequate resources to continue in operational existence for the foreseeable future. The group therefore continues to adopt the going concern basis in preparing its consolidated interim financial statements.

Β 

3. Taxation

Β 

No corporation tax has been provided for in the period due to the projected result for the period not exceeding the losses brought forward.Β Deferred tax assets arising from accelerated capital allowances and trading losses have not been recognised on the basis that their future economic benefit is uncertain.

Β 

4. Profit/(loss) per share

Β 

The calculation of loss per ordinary share is based on a loss Β£73,000 (30 June 2011: Loss Β£74,000, 31 December 2011: loss Β£108,000) and on a weighted average number of shares of 51,112,581 in issue for all periods.

Β 

The outstanding share options are currently anti-dilutive.

Β 

5. Interim financial information

Β 

The interim financial information for the period ended 30 June 2012 is unaudited and does not constitute statutory accounts within the meaning of Section 434 of the Companies Act 2006. The interim financial information for the period ended 30 June 2011 are also unaudited and were approved by the Board of Directors on 29 September 2011. The comparative figures for the financial year ended 31 December 2011 are extracted from the audited accounts for that period. The Company's annual report and financial statements for the year ended 31 December 2011 which were prepared under International Financial Reporting Standards (IFRS) as adopted by the European Union, International Financial Reporting Interpretations Committee (IFRIC) interpretations and with those parts of the Companies Act 2006 applicable to companies reporting under IFRS. The standards used are those published by the International Accounting Standards Board (IASB) and endorsed by the EU at the time of preparing those statements. The annual report and financial statements have been delivered to the Registrar of Companies with an unqualified audit report.

Β 

Copies of the announcement will be sent to shareholders and are available to members of the general public from the Company Secretary, Inditherm plc, Inditherm House, Houndhill Park, Bolton Road, Wath upon Dearne, S63 7LG or via the Company website at www.indithermplc.com.

Β 

Β 

This information is provided by RNS
The company news service from the London Stock Exchange
Β 
END
Β 
Β 
IR PGUCCBUPPGAQ
Date   Source Headline
3rd Oct 20177:00 amRNSNeuroproteXeon and Mallinckrodt licence agreement
26th Sep 20177:00 amRNSInterim Results
11th Sep 20177:00 amRNSTR1 Notification of Major Interest in Shares
31st Aug 20177:00 amRNSOperational Appointments
25th Aug 20177:00 amRNSTrading Update and Notice of Results
17th Aug 20177:00 amRNSCapital Reduction
14th Aug 20177:00 amRNSInvestors Open Day
31st Jul 20172:45 pmRNSCapital Reduction
30th Jun 201712:01 pmRNSResult of AGM
30th Jun 20177:00 amRNSAGM Statement
19th May 20177:00 amRNSPosting of Annual Report and Notice of AGM
3rd May 20177:00 amRNSPreliminary Results
4th Apr 20174:25 pmRNSNotice of Results
4th Apr 20172:38 pmRNSHolding(s) in Company
6th Feb 20177:00 amRNSNew Corporate Office & Change of Registered Office
5th Dec 20161:05 pmRNSRevised Notification of Major Interest In Shares
28th Nov 201610:50 amRNSTR1 Notification of Major Interest in Shares
28th Nov 201610:50 amRNSTR1 Notification of Major Interest in Shares
24th Nov 20166:02 pmRNSTR1- Notification of Major Interest in Shares
23rd Nov 20161:16 pmRNSSecondary Placing
14th Nov 20167:00 amRNSTwo new products launched at MEDICA 2016
25th Oct 20161:38 pmRNSProposal for reduction in share premium account
19th Oct 20169:00 amRNSOffice Changes and Outsourcing of Warming Products
28th Sep 20167:00 amRNSHalf-year Report
22nd Sep 20169:53 amRNSResult of Meeting
9th Sep 20167:00 amRNSChange of Adviser
30th Aug 20167:00 amRNSAppointment of Chief Financial Officer
24th Aug 20167:00 amRNSTrading Update and Notice of Results
19th Aug 20167:00 amRNSProposed Capital Reduction and Notice of GM
22nd Jun 20161:41 pmRNSResult of AGM
22nd Jun 20167:00 amRNSAGM Statement
9th Jun 20167:00 amRNSAgreements with Atom Medical and EPMC Pharma
16th May 20167:00 amRNSDirectorate Change
12th May 20163:16 pmRNSAnnual Report
28th Apr 20167:00 amRNSFinal Results
7th Mar 20167:00 amRNSCE mark granted for disposable medical device
22nd Feb 20167:00 amRNSTrading Update
11th Jan 20164:32 pmRNSDirectors' Interests & Substantial Shareholdings
18th Nov 20157:00 amRNSAgreement signed with Bio-Med Devices Inc.
29th Sep 20157:00 amRNSInterim Results
18th Aug 20157:00 amRNSChange of Accounting Reference Date
3rd Aug 20157:00 amRNSAppointment of Non-Executive Director
23rd Jun 20154:59 pmRNSChange of Name and ISIN/SEDOL Numbers
23rd Jun 201512:08 pmRNSResult of General Meeting
11th Jun 20151:27 pmRNSResult of AGM
8th Jun 20157:30 amRNSSchedule One - Inditherm plc
26th May 20157:01 amRNSProposed Acquisition of Inspiration Healthcare
30th Apr 20157:00 amRNSPublication of Annual Report
22nd Apr 20159:58 amRNSHolding(s) in Company
16th Apr 20157:00 amRNSFinal Results

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.